文献速递胰腺与胆道疾病消化内镜

EUS引导胆囊引流与经皮胆囊造瘘术治疗急性胆囊炎的试验序贯分析

Trial sequential analysis of EUS-guided gallbladder drainage versus percutaneous cholecystostomy in patients with acute cholecystitis.
PubMed 文献 · Gastrointest Endosc · 2021-09-23

该研究对截至2021年7月的比较EUS引导胆囊引流(EUS-GBD)与经皮胆囊造瘘术(PT-GBD)治疗急性胆囊炎的研究进行常规荟萃分析和试验序贯分析(TSA)。共纳入4项研究535例患者,TSA评估所需信息量(RIS)以验证结果的可靠性。结果显示PT-GBD技术成功率可能更优但需大样本验证,临床成功率相似,EUS-GBD显著降低总体不良事件和非计划再入院,但再干预需求需进一步研究。

要点

  • EUS-GBD显著降低总体不良事件和非计划再入院,TSA确认结论可靠。
  • PT-GBD技术成功率可能更优,但需1663例样本以避免假阳性。
  • EUS-GBD再干预较少,但TSA未排除假阳性,需额外97例验证。

核心结论

  • 若积累极大样本,PT-GBD技术成功率可能优于EUS-GBD,但单患者获益有限。
  • 临床成功率两者可能相当。
  • EUS-GBD令人信服地减少总体不良事件和非计划再入院;再干预需求需进一步研究。

研究设计与样本

  • 对截至2021年7月比较EUS-GBD(使用腔壁贴合金属支架)与PT-GBD治疗急性胆囊炎的研究进行常规荟萃分析和试验序贯分析(TSA)。
  • 共纳入4项研究,累计535例患者。

临床怎么用

  • EUS-GBD可考虑用于减少不良事件和再入院,但技术成功率可能略低于PT-GBD。
  • 临床决策时应权衡EUS-GBD降低不良事件与PT-GBD技术成功可能更优的潜在差异。
  • 再干预需求的比较证据尚不充分,需更多研究。

局限性

  • 仅纳入4项研究,样本量535例,部分结局未达到所需信息量。
  • 技术成功和再干预的TSA未排除I型错误,结论需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Meta-analytic comparison of EUS-guided gallbladder drainage (EUS-GBD) versus percutaneous gallbladder drainage (PT-GBD) for acute cholecystitis (AC) brings the risk of spurious results if too few studies are included. Trial sequential analysis (TSA) can overcome this, providing information about its credibility. METHODS: Comparative studies between EUS-GBD, using lumen-apposing metal stents, and PT-GBD for AC until July 2021 were used for conventional meta-analysis and TSA, which allowed the use of monitoring boundaries and the estimation of the required information size (RIS) needed to prove credibility. RESULTS: Four studies accrued 535 patients. Technical success was in favor of PT-GBD (relative risk [RR], .967; P = .036), but TSA estimated that 1663 participants would be needed to avoid a Type I error (false positive). Clinical success was similar (RR, .965; P = .146), and TSA supported the absence of any demonstrable superiority of one therapy rather than a Type II error (false negative). EUS-GBD reduced overall adverse events (RR, .424; P < .001) and unplanned readmissions (RR, .215; P < .001), and TSA confirmed the avoidance of a Type I error, with early RIS achievement, providing necessary credibility. EUS-GBD had fewer reinterventions (RR, .244; P < .001), but a Type I error was not avoided, needing additional 97 patients to the accrued 535 to prove credibility. CONCLUSIONS: PT-GBD can provide superior technical success than EUS-GBD if a very large sample size is accrued, thus limiting the single-patient benefit. Clinical success is probably equivalent. EUS-GBD convincingly decreased overall adverse events and unplanned readmissions, whereas the need for reinterventions requires additional studies.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Cucchetti A, Binda C, Dajti E, et al. Trial sequential analysis of EUS-guided gallbladder drainage versus percutaneous cholecystostomy in patients with acute cholecystitis. Gastrointest Endosc. 2021. PMID: 34563502. doi:10.1016/j.gie.2021.09.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。